A new study finds that more than one-third of heart failure (HF) patients do not receive recommended HF-specific medications within 30 days of diagnosis.
A new study finds that more than one-third of heart failure (HF) patients do not receive recommended HF-specific medications within 30 days of diagnosis, and 29% of patients did not have a prescription filled for HF-specific treatments during the median 28-month period patients were followed up.
The finding, published in the May 2016 issue of the Journal of Managed Care & Specialty Pharmacy, confirms earlier studies that have suggested that medication recommendations by the American College of Cardiology Foundation/American Heart Association (ACCF/AHA) for a combination of angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor II blockers (ARB) and beta blockers (BB) are underprescribed for the management of HF. The guidelines also recommend aldosterone antagonists (AA) as add-on therapy for all patients with persisting symptoms despite treatment with ACEIs/ARBs and BBs.
The study used administrative claims of 235,758 newly diagnosed HF patients in the Truven Health MarketScan Commercial Claims and Encounters database and the Medicare Supplemental and Coordination of Benefits database of adult patients with at least 2 medical claims within 12 months on different dates corresponding to a HF diagnosis during the period from April 1, 2009, to March 31, 2012. Their mean age was 70.9 years with 46.5% aged 75 years or greater, and 51.6% of the cohort was female.
Overall, 41.8% of patients did not have any single prescription fill for HF-specific treatments of interest (ACEIs, ARBs, BBs and AAs) within 30 days of their first diagnosis. Even after taking diuretics into consideration, 35.5% of patients did not have an HF-specific treatment prescribed within 30 days of initial diagnosis. Among patients treated with HF-specific treatments, prescriptions for ACEI were filled by 46.2%, ARBs by 17.07%, BBs by 75.62%, and AAs by 9.83%. In all, 51.3% of patients had prescription fills for monotherapy, and 40% for bi-therapy. More than 80% of patients had treatment modification during the median 28 months of follow-up.
A total of 74% of patients had at least 1 all-cause hospitalization per year. Within 12 months after the index visit, 85.7% of these patients experienced an all-cause hospitalization, with 29.6% having HF-related hospitalization. More than 60% of patients continued on the same therapy after all-cause or HF hospitalization. More patients on multiple therapies remained on the same treatment compared with those treated with monotherapy after the first HF hospitalization. During the entire study period, 29% of patients did not have a prescription fill for HF-specific treatments.
The investigators say their findings suggest that despite ACCF/AHA recommendations of initiating treatment with a combination of 2 HF drug classes, only 40% of patients had a prescription fill for bi-therapy. Hospitalization did not have a major impact on HF therapy prescribing patterns. The analysis reveals the need for further research to better understand why there is a delay in HF treatment initiation and limited use of guideline-directed medical therapy after HF diagnosis.
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More